R. Michael Carruthers
2016 - Nivalis Therapeutics
In 2016, R. Michael Carruthers earned a total compensation of $1.1M as Former Interim President and Chief Financial Officer at Nivalis Therapeutics, a 36% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $124,950 |
|---|---|
| Option Awards | $593,230 |
| Salary | $357,000 |
| Other | $7,950 |
| Total | $1,083,130 |
Carruthers received $593.2K in option awards, accounting for 55% of the total pay in 2016.
Carruthers also received $125K in non-equity incentive plan, $357K in salary and $8K in other compensation.
Rankings
In 2016, R. Michael Carruthers' compensation ranked 7,859th out of 14,075 executives tracked by ExecPay. In other words, Carruthers earned more than 44.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,859 out of 14,075 | 44th |
Division Manufacturing | 2,990 out of 5,489 | 46th |
Major group Chemicals And Allied Products | 993 out of 1,895 | 48th |
Industry group Drugs | 769 out of 1,538 | 50th |
Industry Pharmaceutical Preparations | 612 out of 1,176 | 48th |
Source: SEC filing on April 24, 2018.
Carruthers' colleagues
We found four more compensation records of executives who worked with R. Michael Carruthers at Nivalis Therapeutics in 2016.